In contrast to previous studies, the incidence of bowel obstruction (including ileus, intussusception, volvulus, neurogenic bowel, megacolon, and other types of bowel obstruction) was not found to differ between SGLT-2 inhibitors and GLP-1RAs but tended to be nonsignificantly protective against these diagnoses (adjusted HR 0.83 [95% CI 0.69 to 1.01]). The gene discussed is SLC5A2; the disease is intestinal obstruction.